共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
3.
4.
《International journal of urology》2017,24(2):97-101
Photodynamic therapy using 5‐aminolevulinic acid is a treatment method in which the fluorescent substance of protoporphyrin IX excessively accumulated specifically in cancer cells is excited by visible red or green light irradiation, and reactive oxygen is produced and injures cancer cells. Photodynamic therapy using 5‐aminolevulinic acid less markedly influences the surrounding normal cells and tissue as a result of no accumulation of protoporphyrin IX, being a low‐invasive, less harmful treatment localized to cancer. Furthermore, photodynamic therapy using 5‐aminolevulinic acid is painless, requiring no anesthesia because localized lesions are treated at a low‐energy level, and repeatedly applicable, unlike radiotherapy, and so is expected to be a new low‐invasive treatment based on a concept completely different from existing treatments. In fact, photodynamic therapy using 5‐aminolevulinic acid for bladder cancer was clinically demonstrated mainly for treatment‐resistant bladder carcinoma in situ, and favorable outcomes have been obtained. Photodynamic therapy using 5‐aminolevulinic acid are photodynamic technologies based on the common biological characteristic of cancers, and are expected as novel therapeutic strategies for many types of cancer. 相似文献
5.
6.
mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients 总被引:5,自引:0,他引:5
BACKGROUND: The aim of this multicenter study was to assess tumor response, clinical quality-of-life benefit, survival, and safety after treatment with mTHPC in patients with recurrent/refractory squamous cell carcinoma of the head and neck unsuccessfully treated or unsuitable for treatment with conventional modalities. METHODS: One hundred twenty-eight patients were treated with mTHPC followed, 96 hours later, by illumination of the tumor surface with 652-nm laser light. Tumor response was assessed with WHO criteria and tumor mass reduction from baseline. Clinical quality-of-life benefit was based on the University of Washington Quality-of-Life questionnaire. RESULTS: By use of WHO criteria, 38% of evaluable patients achieved an overall tumor response, and 16% achieved a complete tumor response. Forty-three percent of assessable lesions achieved 100% tumor mass reduction, and 58% achieved 50% or greater tumor mass reduction. Fifty-three percent of evaluable patients experienced significant clinical quality-of-life benefit. Subset analyses revealed two subgroups in which significantly better responses were seen in patients with tumors 10 mm or less in depth and patients with fully illuminated lesions. In patients fulfilling both categories, overall tumor response was 54%, complete tumor response was 30%, and 61% demonstrated significant clinical quality-of-life benefit. Median survival was significantly better in responders. No major toxicities were detected. CONCLUSIONS: Patients with advanced cancer of the head and neck, who have exhausted other treatment options, can achieve significant clinical benefit and improvement in quality of life with mTHPC. 相似文献
7.
Sentinel node biopsy for early‐stage oral cavity cancer: the VU University Medical Center experience 下载免费PDF全文
Inne J. Den Toom Bsc Derrek A. Heuveling MD PhD Géke B. Flach MD Stijn van Weert MD K. Hakki Karagozoglu MD DDS Annelies van Schie MD Elisabeth Bloemena MD PhD C. René Leemans MD PhD Remco de Bree MD PhD 《Head & neck》2015,37(4):573-578
8.
9.
Elizabeth Obi Martin C. Tom Bindu V. Manyam Stephen R. Grobmyer Zahraa Al‐Hilli Stephanie Valente Alicia Fanning Diane M. Radford Sheen Cherian Rahul D. Tendulkar Chirag Shah 《The breast journal》2020,26(3):454-457
Adjuvant radiation therapy has been associated with improved local control following breast‐conserving surgery. Traditionally, treatment has been delivered with whole breast irradiation over 3‐6 weeks or partial breast irradiation over 1‐3 weeks. However, intraoperative radiation therapy (IORT) has emerged as a technique that delivers a single dose of radiotherapy at the time of surgery for early‐stage breast cancers. We report initial outcomes and acute toxicities with intraoperative radiation from a single institution. Patients with DCIS or Stage I‐II breast cancer who underwent lumpectomy and sentinel lymph node biopsy (nodal sampling excluded in some cases) were included. All patients in this analysis were treated with IORT as at the time of surgery, 20 Gy in 1 fraction with 50 kV x‐ray. Patients were treated at a single institution between 2011 and 2019. Follow‐up was per standard institutional protocol. Two hundred and one patients were included in the analysis, with a median follow‐up of 23 months (range: 0‐73 months). Median age was 71 years old. Overall, 4 (2.0%) patients had DCIS, 186 (92.5%) patients had Stage 1 disease, and 11 patients had (5.5%) Stage 2 disease. All patients were estrogen receptor‐positive, 175 (87.9%) progesterone receptor‐positive, and 1 (0.5%) HER2 amplified. The crude rate of local recurrence was 2.0% (n = 4) and distant metastasis rate was 0.5% (n = 1). The rate of arm lymphedema was 0.5% (n = 1) and chronic telangiectasia rate was 1.1% (n = 2). Intraoperative radiation therapy, in a cohort of low‐risk patients, demonstrated low rates of recurrence and reproducibility in a multi‐disciplinary setting. Further follow‐up, analysis of patient satisfaction and cosmesis, and comparison to whole breast irradiation and partial breast techniques is necessary in order to further validate these findings. 相似文献
10.
11.
12.
13.
14.
15.
16.
Oncologic outcomes of surgically treated early‐stage oropharyngeal squamous cell carcinoma 下载免费PDF全文
Jason I. Kass MD PhD Laureano Giraldez MD William Gooding MS Garret Choby MD Seungwon Kim MD Brett Miles MD DDS Marita Teng MD Andrew G. Sikora MD PhD Jonas T. Johnson MD Eugene N. Myers MD Umamaheswar Duvvuri MD PhD Eric M. Genden MD Robert L. Ferris MD PhD 《Head & neck》2016,38(10):1467-1471
17.
Clinical significance of melanoma‐associated antigen A1–6 expression in sputum of patients with squamous cell carcinoma of the larynx and hypopharynx 下载免费PDF全文
Kang Dae Lee MD PhD Hyoung Shin Lee MD Sung Won Kim MD Taejung Park MD Jong Chul Hong MD PhD Hee Kyung Chang MD PhD Sang Bong Jung MD PhD Chang‐Ho Jeon MD PhD Jong Wook Park MD PhD 《Head & neck》2016,38(Z1):E736-E740
18.
Boris Schlenker Derya Tilki Michael Seitz Markus J. Bader Oliver Reich Peter Schneede Edwin Hungerhuber Christian G. Stief Christian Gratzke 《BJU international》2010,106(6):786-790
Study Type – Therapy (case series)Level of Evidence 4
OBJECTIVE
To retrospectively analyse the long‐term follow‐up of 54 patients treated with organ‐preserving laser therapy for penile carcinoma, as such therapy provides excellent cosmetic and functional results, but recurrence rates are high, which might impair the oncological outcome and worsen tumour‐related survival.PATIENTS AND METHODS
Between 1979 and 2008, 54 patients with penile carcinoma were treated with the neodymium‐doped yttrium‐aluminium‐garnet (Nd:YAG) laser at our institution; 11 were classified as having carcinoma in situ (Tis), 39 as T1 and four as T2.RESULTS
There was local recurrence in 16 patients (42%); the mean (range) time to local recurrence was 53 (9–132) months. In half the patients the time to local recurrence was >53 months, with the latest recurrence at 132 months after initial therapy of primary tumour. There was no statistically significant difference in recurrence rates with Tis or invasive penile carcinoma. In lymph‐node‐negative patients at initial presentation, there were no newly developed positive lymph nodes during the follow‐up.CONCLUSIONS
Organ‐preserving laser therapy showed a relatively high recurrence rate in patients with a long‐term follow up, but the oncological outcome and survival were not compromised by local recurrence. Therefore, laser therapy appears to be appropriate for treating premalignant lesions and early stages of penile carcinoma. Patients should be informed about the potential for late recurrence. 相似文献19.
Photodynamic therapy for premalignant lesions of the vulva and vagina: A long‐term follow‐up study 下载免费PDF全文
Min Chul Choi MD Mi Sun Kim MD Gee Hoon Lee MD Sang Geun Jung MD PhD Hyun Park MD PhD Won Duk Joo MD PhD Chan Lee MD PhD Je Ho Lee MD PhD Yoon Young Hwang MD PhD Seung Jo Kim MD PhD 《Lasers in surgery and medicine》2015,47(7):566-570
20.
Primary laryngeal small cell neuroendocrine carcinoma (SCNC) is an unusual malignancy accounting for <0.5% of laryngeal carcinomas. To date, approximately 200 cases of primary and 5 of secondary SCNC of the larynx have been reported. This tumor most often presents in the sixth and seventh decades in men who are heavy cigarette smokers. The lesion may be associated with different paraneoplastic syndromes (ectopic adrenocorticotropic hormone syndrome, Schwartz-Bartter syndrome or syndrome of inappropriate secretion of antidiuretic hormone, and Eaton-Lambert myasthenic syndrome) or with ectopic hormone production. The diagnosis is based essentially on the histologic appearance of the tumor, confirmed by immunocytochemical investigations. Concurrent chemoradiotherapy regimens offer potential for long-term survival. This tumor is biologically aggressive, and the extent of the disease is the most significant independent prognostic factor of survival. The survival rate is similar to that with pulmonary SCNC. 相似文献